SafeHeal, a young Franco-American medtech specializing in colorectal surgery, has just closed a €35 million Series C round. The round was led by Solar Eclipse alongside two new investors - Gideon Strategic Partners and M&L Healthcare - with participation from existing investors including Sofinnova Partners. Under the leadership of Chris Richardson, CEO and President, the company is preparing to bring its flagship device Colovac to market, designed to reduce post-operative complications from colon procedures. According to Bpifrance data on French medtech, more than €600 million was raised by medtechs in 2024-2025, a sign of the segment's maturity.
The context behind SafeHeal's Series C round
Moving to Series C marks a key milestone for a medtech: it usually corresponds to the final phase of clinical validation and preparation for commercial launch. For SafeHeal, the €35M raised covers several milestones:
- Completing the pivotal clinical trials for Colovac, the regulatory basis for marketing authorizations;
- Preparing CE marking and FDA authorization, with requirements tightened by the European IVDR/MDR and the US De Novo or 510(k) pathways;
- Building the commercial organization in the US and Europe;
- Scaling up manufacturing and the supply chain to absorb a multi-country launch.
The arrival of Solar Eclipse as lead investor, along with Gideon Strategic Partners and M&L Healthcare, reflects the broadening of the shareholder base ahead of the launch. The continued involvement of existing investors such as Sofinnova Partners signals confidence in the technical and clinical trajectory. As Les Echos noted in a recent column on French medtech, this pattern - a new lead + follow-on from existing investors - is typical of medtech Series C rounds preparing a transatlantic commercial launch.
Profile and geographic footprint
SafeHeal is based in Paris and Tampa, Florida. This dual location is consistent with a Franco-American medtech strategy: R&D and clinical operations run from Paris, with a US team close to the trial sites and the American market, which accounts for the majority of a surgical medtech's value.
Colovac: what the device does
Colovac is an implantable medical device designed to protect colonic anastomoses (the junction sewn back together after removal of a section of the colon). Anastomotic leak is one of the most serious complications of colorectal surgery, with an estimated leak rate of 5 to 20% depending on the type of procedure, and significant associated mortality. To reduce this risk, standard practice often requires a temporary protective stoma (ileostomy or colostomy), with a major impact on the patient's quality of life and a second surgical procedure for closure.
Colovac aims to offer an alternative to this protective stoma by securing the anastomosis during the critical healing phase. The clinical promise is twofold: preserve the patient's quality of life and reduce hospital costs related to re-interventions and extended stays.
A broad clinical target
According to estimates reported by Maddyness in its coverage of the French medtech segment, more than 350,000 colorectal resections are performed each year in the United States and Europe. A significant fraction of these patients carries an increased risk of anastomotic leak that justifies protection - a potential commercial target for Colovac.
The colorectal surgery market and the pressure on quality of life
Colorectal surgery is one of the most active segments in medtech innovation. Three structural drivers are fueling demand for devices like Colovac:
- An aging population, which increases the prevalence of colorectal cancer and inflammatory bowel disease;
- Pressure to improve post-operative quality of life, measured through PROMs (Patient-Reported Outcome Measures), which now weigh into reimbursement decisions;
- The push for hospital efficiency, with a drive to reduce re-interventions, a major source of avoidable costs.
As FrenchWeb noted in an analysis of digital health and medical devices, the alignment between clinical improvement and cost reduction is a central argument for getting an innovative device into hospital protocols and securing adequate reimbursement.
Competitors and positioning
The anastomotic fistula prevention segment is dominated by the leaders in staple line reinforcement (Medtronic, Johnson & Johnson, Baxter via Synovis) and by the providers of leak-testing or intraoperative imaging solutions. SafeHeal stands out by offering a device specifically designed to provide an alternative to the temporary stoma - a differentiated positioning that addresses an unmet clinical need.
The challenges of bringing a surgical device to market
Successfully launching Colovac means solving several equations:
- Generating robust clinical evidence (pivotal randomized trial, publications in high-impact journals);
- Obtaining CE marking and FDA clearance on a timeline compatible with the company's cash position;
- Reimbursement strategy country by country - CPT/HCPCS codes in the United States, GHM/CCAM in France, and their German and UK equivalents;
- Surgeon adoption, which depends on key opinion leaders and professional societies (American Society of Colon and Rectal Surgeons, European Society of Coloproctology).
For teams focused on growth in B2B medtech, this last point is central: the adoption of a surgical device runs through KOLs and training programs, far more than through traditional sales prospecting.
The role of data and AI in colorectal surgery
The rapid evolution of intraoperative imaging (ICG fluorescence, AI-assisted surgical decision-making) is reshaping clinical practice. The applications of AI in surgery now make it possible to assess tissue perfusion in real time, a key predictor of fistula risk. For SafeHeal, this shift is complementary rather than competitive: Colovac provides protection during the healing period, independently of intraoperative diagnostic tools.
Timeline and next steps
SafeHeal's management has not shared a detailed timeline, but several milestones can be anticipated: publication of pivotal trial results, US and EU regulatory submissions, first pilot hospital contracts, then a commercial ramp-up within 12 to 24 months following marketing authorizations. The €35M cash position should be enough to fund this sequence with reasonable headroom, provided the regulatory timeline stays on track.
FAQ
How much has SafeHeal raised in its Series C?
SafeHeal has completed a €35 million Series C funding round led by Solar Eclipse, with participation from Gideon Strategic Partners, M&L Healthcare, and existing investors including Sofinnova Partners.
Who leads SafeHeal?
Chris Richardson is CEO and President of SafeHeal. The company is based in Paris and Tampa, Florida.
What does Colovac do?
Colovac is an implantable medical device designed to protect colonic anastomoses after colon surgery. Its purpose is to provide an alternative to the temporary stoma usually created to reduce the risk of anastomotic leak, one of the most serious complications of colorectal surgery.
Why is preventing anastomotic leaks a major challenge?
The anastomotic leak rate after colorectal surgery is estimated at between 5% and 20% depending on the type of procedure. This complication leads to reoperations, extended hospital stays, and a significant impact on quality of life - especially when a temporary stoma is created to prevent it.
What will the €35M raised be used for?
The funds will be used to complete Colovac's pivotal clinical trials, prepare for CE marking and FDA approval, build a sales organization in Europe and the United States, and strengthen the manufacturing chain ahead of the commercial launch.